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Background: Currently, there is a lack of studies examining the effects of adenosine-5′-triphosphate (ATP)
supplementation utilizing a long-term, periodized resistance-training program (RT) in resistance-trained populations.
Therefore, we investigated the effects of 12 weeks of 400 mg per day of oral ATP on muscular adaptations in
trained individuals. We also sought to determine the effects of ATP on muscle protein breakdown, cortisol, and
performance during an overreaching cycle.
Methods: The study was a 3-phase randomized, double-blind, and placebo- and diet-controlled intervention. Phase
1 was a periodized resistance-training program. Phase 2 consisted of a two week overreaching cycle in which
volume and frequency were increased followed by a 2-week taper (Phase 3). Muscle mass, strength, and power
were examined at weeks 0, 4, 8, and 12 to assess the chronic effects of ATP; assessment performance variables also
occurred at the end of weeks 9 and 10, corresponding to the mid and endpoints of the overreaching cycle.
Results: There were time (p < 0.001), and group x time effects for increased total body strength (+55.3 ± 6.0 kg
ATP vs. + 22.4 ± 7.1 kg placebo, p < 0.001); increased vertical jump power (+ 796 ± 75 ATP vs. 614 ± 52 watts
placebo, p < 0.001); and greater ultrasound determined muscle thickness (+4.9 ± 1.0 ATP vs. (2.5 ± 0.6 mm placebo,
p < 0.02) with ATP supplementation. During the overreaching cycle, there were group x time effects for strength
and power, which decreased to a greater extent in the placebo group. Protein breakdown was also lower in the
ATP group.
Conclusions: Our results suggest oral ATP supplementation may enhance muscular adaptations following 12-weeks
of resistance training, and prevent decrements in performance following overreaching. No statistically or clinically
significant changes in blood chemistry or hematology were observed.
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Adenosine-5′-triphosphate’s (ATP) role as the primary
intracellular energy source for body tissues is well
established [1]. In addition, ATP also has extensive extra-
cellular functions that are primarily mediated through
purinergic (P2Y and P2X) membrane receptors ubiqui-
tously present in many cell types [2]. One extracellular-
mediated function of ATP includes the modification of
muscle excitability (i.e., increasing skeletal muscle calcium
permeability and blocking chloride efflux) and vasodila-
tion [3,4]. Moreover as a co-transmitter, ATP operates on
both the central and peripheral nervous systems to elicit
local tissue modifications during neurotransmission [5].
It has been reported that the half-life of infused ATP
is less than one second [6-8], ATP is rapidly taken up
and stored by erythrocytes [6]. This rapid uptake by
erythrocytes is central to its role in affecting blood flow
and oxygen delivery to oxygen-depleted tissue [9].
Specifically, there is a tight coupling between oxygen
demand in skeletal muscle and increases in blood flow.
Erythrocytes regulate this response by acting as “oxygen
sensors” [10]. When oxygen is low in a working muscle
region, the red blood cell deforms, and releases ATP
[10,11]. The result is vasodilation and greater blood flow
to the working musculature, thereby enhancing nutrient
and oxygen delivery [10,11]. Long-term oral administra-
tion of ATP has been shown to increase both the uptake
and synthesis of ATP in the erythrocytes of rodents [12].
Collectively, these findings suggest that oral ATP supple-
mentation may elicit ergogenic outcomes on skeletal
muscle without elevating plasma ATP concentrations.
Research by Jordan et al. [13] demonstrated that 225 mg
per day of enteric-coated ATP supplementation for
15 days resulted in increased total bench press lifting
volume (i.e. sets•repetitions•load [kg]) as well as within-
group set-one repetitions to failure. More recently,
Rathmacher et al. [14] found that 15 days of 400 mg per
day of ATP supplementation increased minimum peak
torque for the final two sets of a dynamometer test. The
increases suggest that orally delivered ATP may reduce
muscle fatigue and enable a higher force output during
repeated high-intensity bouts of exercise. These aforemen-
tioned findings lead us to hypothesize that dietary supple-
mentation with ATP may be beneficial to both the
exercising and less active muscle tissue.
The novelty of ATP as an oral supplement has limited
data available in regards to its chronic effects in humans.
To date, no studies have examined the chronic effects of
oral ATP supplementation on body composition or indi-
cators of athletic performance when combined with a
periodized resistance training (RT) protocol. However,
provided that short-term supplementation in the ab-
sence of a training intervention has resulted in positive
outcomes in muscle performance, it is plausible tosuggest that ATP may have long-term ergogenic effects
in periodized RT regimens. Therefore, the primary pur-
pose of this study was to test the hypothesis that supple-
mentation with oral ATP would improve measures of
power, strength, and skeletal muscle mass during a
12-week RT protocol. The second purpose was to assess
the safety of the supplement over 12 weeks through
blood chemistry and hematology measures.
Methods
Study design
This was a randomized, double-blind, placebo- and diet-
controlled, parallel groups with repeated measures study
design. Both groups were assigned to a 12-week perio-
dized RT protocol. Blinding occurred via an outside
researcher who sent the supplement and placebo in
identical opaque capsules. This researcher was not in-
volved in direct data collection, and did not meet any of
the subjects. For this reason neither the researchers
conducting the study nor the subjects knew who was in
each group. Moreover the code was not broken until
after all of the data were entered into Microsoft® Excel,
and sent to an outside researcher who was also blinded
to the treatment groups. The protocol was divided into
three phases. Phase one consisted of a three times per
week non-linear periodized RT program for weeks 1–8,
modified from Kraemer et al. [15]. Phase two consisted
of a two-week overreaching cycle during weeks 9 and
10. Finally, phase three consisted of participants tapering
for weeks 11 and 12. Muscle mass and body composition
were measured at baseline and at the end of weeks 4, 8,
and 12. Muscle strength, vertical jump power, Wingate
peak power (PP), creatine kinase (CK), C-reactive pro-
tein (CRP), free and total testosterone, and perceived re-
covery were measured at baseline and after weeks 4, 8,
9, 10 and 12. Additionally, CK, CRP, free and total testos-
terone, and perceived recovery were measured after week
1 of training. Protein breakdown was assessed using urin-
ary 3-methylhistidine: Creatinine ratio (3-MH:Cr) at base-
line and after weeks 1 and during the overreaching phase
at weeks 8, 9, and 10. These variables were used to assess
the effects of ATP on performance, hormone status, and
indices of muscle damage and recovery during an
overreaching cycle. The ClinicalTrials.gov registration ID
was NCT01508338.
Participants
Twenty-four resistance-trained males were selected for
the study. However, due to injury three subjects dropped
out of the study leaving 21 subjects (11 ATP sup-
plemented and 10 placebo supplemented) aged 23.4 ±
0.7 years, with an average one-repetition maximum
(1RM) squat, bench press, and deadlift of 1.71 ± 0.04,
1.34 ± 0.03 and 2.05 ± 0.04 times their bodyweight were
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pate if they were taking an anti-inflammatory agent, a
performance-enhancing supplement, if they smoked, or
if they had consumed nutritional supplements during
the three months prior to data collection. Each par-
ticipant signed an informed consent approved by the
University of Tampa Institutional Review Board before
participating in the study.
Muscle strength, power, body composition and skeletal
muscle hypertrophy testing
After familiarization procedures, muscle strength was
assessed via 1RM testing of the back squat, bench press,
and deadlift. Each lift was performed as described by the
International Powerlifting Federation rules [16]. We
used an intraclass correlation coefficient (ICC) (2,k)
formula [17] to determine the reliability of repeated
measures within testers. The ICC for strength measures
ranged from 0.96 to 0.98. Body composition (lean body
mass, fat mass, and total mass) was determined by dual-
energy x-ray absorptiometry (DXA; Lunar Prodigy
enCORE 2008, Madison, Wisconsin, U.S.A.). Skeletal
muscle hypertrophy was determined via the combined
changes in ultrasonography-determined muscle thick-
ness of the vastus lateralis (VL) and vastus intermedius
(VI) muscles. The mean of three measurements by the
same blinded investigator were taken at 50% of femur
length over the mid-belly of the muscle with the subjects
lying in a supine position. The precision for the test-
retest of muscle thickness measurements was 0.975.
Muscle power was assessed during maximal cycling
and jumping movements. During the cycling test, volun-
teers were instructed to cycle against a predetermined
resistance (7.5% of body weight) as fast as possible for
10 seconds [18]. The saddle height was adjusted to the
individual’s height to produce a 5–10° knee flexion while
the foot was in the low position of the central void. A
standardized verbal stimulus was provided to each
participant. Power output was recorded in real time du-
ring the 10-second sprint test, by a computer connected
to the standard cycle ergometer (Monark model 894e,
Vansbro, Sweden). Peak power (PP) was recorded using
Monark Anaerobic Wingate Software, Version 1.0
(Monark, Vansbro, Sweden). The ICC of muscle peak
power was 0.96.
Measurements of PP were also taken during a vertical
jump (VJ) test performed on a multicomponent AMTI
force platform (Advanced Mechanical Technology, Inc.,
Watertown, MA), interfaced with a personal computer
at a sampling rate of 1000 Hz [19]. Data acquisition
software (LabVIEW, version 7.1; National Instruments
Corporation, Austin, TX) was used to calculate PP. Peak
power was calculated as the peak combination of
ground reaction force and peak velocity during theaccelerated launch on the platform. The ICC of VJ
power was 0.97.
Supplementation and diet control
Prior to the study, participants were randomly assigned to
receive either 400 mg per day of ATP disodium or malto-
dextrin (placebo), consumed orally via a two-piece gelatin
capsule 30 minutes prior to RT sessions. On non-training
days, participants were instructed to consume one dose
on an empty stomach prior to breakfast. The placebo and
ATP capsules (400 mg) were obtained directly from the
commercial manufacturer (TSI USA Inc., Missoula, MT)
and were produced in compliance with U.S. cGMPs for
dietary supplements. The Certificate of Analysis for both
the placebo and ATP capsules were provided and verified
the supplement contents. Moreover, we verified the cap-
sule’s purity by HPLC. Two weeks prior to and throughout
the study, participants were placed on a diet consisting of
25% protein, 50% carbohydrates, and 25% fat by a regis-
tered dietician who specialized in sport nutrition. Partici-
pants met as a group with the dietitian, and they were
given individual meal plans two weeks prior to the onset
of the study. Diet counseling was continued on an indi-
vidual basis throughout the study.
Resting blood draws
All blood draws were obtained after an overnight 12-hour
fast via venipuncture by a trained phlebotomist, and were
scheduled at the same time of day to avoid influences of
hormonal variations. Whole blood was collected and
transferred into appropriate tubes and centrifuged at
1500 x g for 15 min at 4°C. Resulting serum and plasma
were then aliquoted and stored at −80°C until subsequent
analyses. A portion of the blood samples taken at weeks 0,
4, 8, and 12 were used for measurements (ANY LAB
TEST NOW®, Tampa, Fl) of glucose, blood urea nitrogen,
creatinine, eGFR, Na, K, Cl, CO2, Ca, protein, albumin,
globulin, albumin:globulin ratio, total bilirubin, alkaline
phosphatase, aspartate aminotransferase, and alanine ami-
notransferase. A complete blood count was also per-
formed on each blood sample. The commercial laboratory
performing the safety analysis was instructed to inform
investigators of any abnormal values in any parameters
measured during the study time points measured. In the
case of an abnormal value, the subject would be told and
not be allowed to continue the study. Because no abnor-
mal values were detected during the study in these healthy
and highly fit subjects, the total aggregate numbers were
not presented to the investigators until the end of the
study.
Biochemical analysis
Samples were thawed once and analyzed in duplicate for
each analyte. Serum free and total testosterone, cortisol,
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kits obtained from Diagnostic Systems Laboratories
(Webster, TX). All hormones were measured within the
same assay and on the same day to avoid compounded
inter-assay variance. Intra-assay variance was less than
3% for all analytes. Serum creatine kinase (CK) was
measured using colorimetric procedures at 340 nm
(Diagnostics Chemicals, Oxford, CT).
Perceived recovery status scale
Perceived Recovery Status (PRS) Scale was measured at
all measurement times and in particular at weeks 8, 9,
and 10 to assess participant recovery during the
overreaching phase. The PRS Scale consists of values be-
tween 0–10, with 0–2 being very poorly recovered and
characterized by anticipated declines in performance;
4–6 is defined as low-to-moderately recovered and cha-
racterized by no expected change in performance; and,
8–10 represents high perceived recovery and correlates
strongly with increases in performance [20].
Statistics
A one-way ANOVA model was used to analyze the base-





Placebo 145.2 ± 10.2 151.6 ± 11.0 156.4 ± 11.6
ATP 146.1 ± 5.8 155.2 ± 7.7 160.7 ± 7.6
Bench Press, kg
Placebo 115.2 ± 9.4 119.3 ± 9.4 121..4 ± 9.3
ATP 117.2 ± 5.5 122.1 ± 5.0 124.5 ± 5.2
Deadlift, kg
Placebo 169.8 ± 11.0 177.0 ± 10.7 182.5 ± 10.7
ATP 176.2 ± 4.9 189.2 ± 5.9 200.3 ± 7.4#
Total Strength, kg
Placebo 430.2 ± 28.1 448.0 ± 28.9 460.2 ± 29.6
ATP 439.4 ± 14.9 466.5 ± 17.1 485.6 ± 18.1#
Wingate Peak Power, Watts
Placebo 882.2 ± 54.1 930.3 ± 55.7 985.3 ± 64.7
ATP 882.8 ± 27.0 960.9 ± 36.1 1003.5 ± 40.4
Vertical Jump power, Watts
Placebo 5318 ± 410 5711 ± 439 5918 ± 443
ATP 5185 ± 203 5618 ± 213 5954 ± 202#
aMean ± SEM for n = 11 ATP (400 mg ATP/d taken 30 min prior to exercise) and n =
bProbability of treatment by time difference between the placebo and the ATP trea
with the main effects of treatment, time and treatment by time, with the value for
#Significantly different than corresponding placebo, t-test (p < 0.05).in SAS® (SAS Institute, Cary, NC). The main effect of
treatment (Trt) was included in the model. Actual values
for muscle strength and power, body composition,
muscle damage, hormonal status, and PRS changes over
the 12-week study were analyzed by using a repeated
measures ANOVA using the Proc Mixed procedure in
SAS®. The initial baseline value (e.g. week 0) was used as
a covariate with the main effects of Time, Trt, and the
interaction Trt*Time in the model. The overreaching
cycle of the study was further assessed by using repeated
measures ANOVAs with the Proc Mixed procedure in
SAS®. Values measured at the week-8 time point were
used as a covariate with the main effects of Time, Trt,
and Trt*Time for the overreaching phase (phase two).
The Least Squares Means procedure was used to com-
pare Trt means at each time point. Statistical signifi-
cance was determined at p ≤ 0.05.
Results
Participant characteristics
There were no differences in age (placebo = 23.0 ± 1.2,
ATP = 23.7 ± 0.9 yrs), height ( placebo = 180.6 ± 2.3, ATP =
179.0 ± 1.0 cm), or body mass (placebo = 87.4 ± 4.3, ATP =
85.7 ± 1.7 between the treatments at the start of the study.d power in participants performing a 12 week weight
of Study
9 10 12 p-valueb
150.7 ± 10.4 147.2 ± 10.7 151.3 ± 10.3
159.0 ± 6.1# 158.6 ± 6.9# 165.3 ± 8.3# <0.001
113.4 ± 7.2 115.7 ± 8.0 119.3 ± 8.7
120.0 ± 4.8 121.2 ± 5.5 124.2 ± 5.4 0.65
173.2 ± 10.8 174.8 ± 8.1 182.0 ± 9.2
193.4 ± 6.4# 193.8 ± 8.3# 205.2 ± 6.9# 0.002
437.3 ± 26.1 437.6 ± 25.1 452.6 ± 25.9
472.4 ± 15.2# 473.6 ± 18.3# 494.7 ± 17.9# <0.001
922.9 ± 61.9 939.9 ± 65.7 977.4 ± 66.5
964.2 ± 38.0 974.7 ± 39.8 1011.9 ± 42.4 0.48
5697 ± 436 5626 ± 431 5932 ± 452
5838 ± 218# 5827 ± 208# 5981 ± 207# <0.001
10 placebo supplemented participants.
tments over the 12-week study. The mixed model ANOVA in SAS® was used
week 0 used as a covariate.
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Both groups increased their muscle strength (Table 1,
Figure 1A, t-test, p < 0.001). However, supplementation
with ATP resulted in significantly greater increases in
the 1RM for the squat, deadlift, and total strength com-
pared with placebo over the 12-week study (Trt*time,
p < 0.001, 0.002, and 0.001, respectively). The ATP sup-
plementation resulted in strength increases of 12.9% and
16.4% for squat and deadlift, respectively. However, in
the placebo group, RT alone resulted in increases of 4.4
and 8.5% for squat and deadlift, respectively. The total
strength increases over the 12-week study were 5.9%
(22.4 ± 7.1 kg) in the placebo-supplemented participants
and 12.6% (55.3 ± 6.0 kg) in the ATP-supplemented
participants (Figure 1A, Trt*time, p < 0.001). Mean total
strength in response to ATP supplementation was
greater at 8, 9, 10, and 12 weeks than mean totalFigure 1 Effects of oral ATP supplementation on total strength and v
sum of the 1-RM in bench press, squat, and deadlift in male participants un
overreaching cycle during weeks 9 and 10. Participants were supplemented
during the 12-week training program. When compared with placebo supp
over the 12 week study (‡ p < 0.001, Trt*time). During the overreaching cy
supplemented group relative to the ATP-supplemented group during wee
supplemented with ATP had greater mean strength at the 8, 9, 10, and 12
(# p < 0.05). (B) Percent change in vertical jump power in male participant
an overreaching cycle during weeks 9 and 10. Participants were suppleme
(n=11) during the training program. ATP supplementation resulted in a gr
(‡ p < 0.001, Trt*time). The increased intensity of the overreaching cycle d
power in the placebo-supplemented participants compared with the ATP-s
Additionally, ATP-supplemented participants had greater vertical jump pow
supplemented participants (# p < 0.05).strength in the placebo-supplemented participants
(t-test, p < 0.05). During phase 2, the overreaching cycle,
the placebo-supplemented group had a 22.6 ± 5.1 kg
decrease in total strength, while the ATP-supplemented
group decreased only 12.0 ± 2.5 kg in total strength
during the same test period (Table 1, Figure 1A, Trt,
p < 0.007).
Muscle power measured by Wingate PP and vertical
jump power increased pre-to-post-test similarly in both
groups during the RT protocol (Table 1 and Figure 1B;
t-test, p < 0.001). However, ATP supplementation signifi-
cantly increased vertical jump power when compared to
placebo (Table 1 and Figure 1B; Trt*time p < 0.001). The
ATP-supplemented participants had a 15.7% (796 ± 75
watts) increase in vertical jump power compared with an
11.6% (614 ± 52 watts) increase in placebo-supplemented
participants over the 12-week period. During phase 2,ertical jump power. (A) Percent change in total strength as the of
dergoing 12 weeks of intense, periodized resistance training with an
with either a Placebo - - ♦- - (n=10) or 400 mg ATP/d —∎— (n=11)
lementation total strength was increased with ATP supplementation
cle of the study, total strength decreased in the placebo-
ks 9 and 10 († p < 0.001, Trt*time). Additionally, participants
week time-points compared with placebo-supplemented participants
s undergoing 12 weeks of intense, periodized resistance training with
nted with either a Placebo - - ♦- - (n=10) or 400 mg ATP /d —∎—
eater increase in vertical jump power over the 12 week study
uring the study resulted in a significant decrease in vertical jump
upplemented participants during weeks 9 and 10 († p < 0.007).
er at 8, 9, 10, and 12 weeks of study compared with placebo-
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ticipants had a 5.0% (−291 ± 25 watts) decrease in power
from week 8 to week 10, while the ATP-supplemented
participants had a 2.2% decrease (−126 ± 19 watts;
Trt*time, p < 0.001).
Body composition and muscle hypertrophy measurement
After 12 weeks of RT, lean body mass (LBM) increased
within both groups (Table 2, t-test, p < 0.001), whereas
fat percentage was decreased with training only in the
ATP-supplemented participants (Table 2 t-test, p <0.01).
The ATP supplementation did not affect overall body
weight or fat percentage during the study, but it did sig-
nificantly increase LBM gain during the 12-week training
period (Trt*time, p < 0.009). The ATP-supplemented
participants gained 4.0 ± 0.4 kg of LBM whereas the
placebo-supplemented participants gained 2.1 ± 0.5 kg of
LBM. The quadriceps muscle thickness increased after
12 weeks of RT (Table 2, Time, p < 0.001). Additionally,
ATP supplementation resulted in a 9.4% (4.9 ± 1.0 mm)
increase in quadriceps muscle thickness compared with
a 4.9% (2.5 ± 0.6 mm) increase in response to placebo
(Table 2, Trt*time p < 0.02).
Muscle damage, hormonal status and performance
recovery scale
Muscle damage assessed by blood CK was affected by
training (Table 3, Time, p < 0.001). Supplementation with
ATP was unable to attenuate the increase in CK at eitherTable 2 Effect of ATP supplementation on body
composition and Quadriceps thickness in participants
performing a 12 week weight training regimen.a
Week of Study
0 4 8 12 p-valueb
Weight, kg
Placebo 87.4 ± 4.3 88.3 ± 4.6 88.7 ± 4.8 87.7 ± 4.7
ATP 85.7 ± 1.7 86.9 ± 2.0 87.0 ± 2.0 87.0 ± 2.1 0.49
DXA LBM, kg
Placebo 68.5 ± 2.6 70.0 ± 2.3 71.2 ± 2.4 70.5 ± 2.4
ATP 67.7 ± 2.0 70.1 ± 1.9 71.4 ± 2.0# 71.7 ± 1.9# .009
DXA Fat,%
Placebo 21.0 ± 1.1 19.8 ± 1.6 18.6 ± 1.9 18.6 ± 1.7
ATP 19.5 ± 1.8 18.1 ± 1.8 16.6 ± 1.6 16.0 ± 1.5 0.76
Quad, mm
Placebo 50.2 ± 2.1 52.2 ± 2.3 52.6 ± 2.4 52.7 ± 2.4
ATP 50.9 ± 0.9 53.4 ± 1.3 54.8 ± 1.7 55.8 ± 1.8# 0.02
aMean ± SEM for n = 11 ATP (400 mg ATP/d taken 30 min prior to exercise)
and n = 10 placebo supplemented participants.
bProbability of treatment by time difference between the placebo and the ATP
treatments over the 12-week study. The mixed model ANOVA in SAS® was
used with the main effects of treatment, time and treatment by time, with the
value for week 0 used as a covariate.
#Significantly different than corresponding placebo, t-test (p < 0.05).the initiation of training (weeks 0 to 1) or during phase
2, the overreaching cycle (weeks 9 and 10), where the
sudden change in training volumes caused blood CK to
increase. Muscle protein degradation was measured by
the urinary 3-MH:Cr ratio (Table 3) during the initiation
of training (weeks 0 to 1) and overreaching cycle (weeks
9 and 10). During week 8 of the study, ATP-sup-
plemented subjects had a higher urinary 3-MH:Cr ratio
compared to the placebo group (t-test, p < 0.05). How-
ever, the 8-week values were not different than baseline
for both treatment groups. The results indicate that
when training volume increased during weeks 9 and 10,
ATP supplementation significantly decreased muscle
protein degradation compared with placebo (Trt*time,
p < 0.007). During phase 2, the overreaching cycle, pro-
tein degradation increased 23.7 ± 4.5% in the placebo-
supplemented, but not ATP supplemented participants.
Supplementation with ATP did not affect changes in
CRP, cortisol, or free or total testosterone levels when
compared with placebo supplementation (Table 3).
Muscle recovery and readiness to train in the next
training session was measured by PRS score (Table 3).
While no overall 12-week Trt*time effect of ATP supple-
mentation was observed, the effects of ATP supplemen-
tation compared with placebo at weeks 10 and 12 may
indicate that ATP supplementation improved perceived
recovery (Table 3).
Safety assessment using blood chemistry and hematology
Blood chemistry and hematology analyses were per-
formed at baseline (week 0) and at weeks 4, 8, and 12 of
the study; the data are shown in Tables 4 and 5, which
displays blood chemistry and hematology values, respec-
tively. No statistically or clinically significant changes in
blood chemistry or hematology were observed over the
12-week ATP supplementation period when compared
with placebo supplementation. There were no adverse
events reported in this study.
Discussion
The primary findings of this study were that individuals
consuming 400 mg of oral ATP daily demonstrated
ergogenic effects with ATP supplementation, since they
showed greater gains in muscle mass, lean body mass,
strength and power when compared to a placebo-
matched control.
The effects of ATP on skeletal muscle strength and power
development
Strength and power are two of the most critical attri-
butes underlying success in athletics [21,22]. These
variables are intimately related and allow athletes to be
successful in their respective sport [23,24]. Prior to our
research, there was limited data evaluating the effects of
Table 3 Blood creatine kinase (CK), urinary 3-methylhistidine (3MH), C-reactive protein (CRP), cortisol, free and total
testosterone, and perceived recovery score (PRS) in participants performing a 12 week weight training regimen
and supplemented with either a placebo or ATP.a
Week of Study
0 1 4 8 9 10 12 p-valueb
CK, IU/L
Placebo 141 ± 12 582 ± 77 373 ± 13 246 ± 29 484 ± 52 528 ± 72 187 ± 21
ATP 145 ± 8 500 ± 71 324 ± 14 234 ± 32 426 ± 44 449 ± 62 160 ± 20 0.91
24 h 3MH:Cr, μmol:mg
Placebo 0.127 ± 0.007 0.130 ± 0.003 Nmc 0.123 ± 0.004 0.134 ± 0.005 0.152 ± 0.005 Nm
ATP 0.136 ± 0.008 0.127 ± 0.007 Nm 0.143 ± 0.007# 0.143 ± 0.008 0.131 ± 0.012# Nm 0.007
CRP, mg/L
Placebo 1.9 ± 0.7 1.1 ± 0.1 1.3 ± 0.3 2.0 ± 0.7 1.6 ± 0.7 1.2 ± 0.2 1.6 ± 0.4
ATP 1.4 ± 0.4 1.1 ± 0.1 1.2 ± 0.2 1.9 ± 0.6 1.7 ± 0.6 1.1 ± 0.1 1.2 ± 0.2 0.99
Cortisol, μg/dL
Placebo 19.7 ± 1.1 20.8 ± 1.3 19.0 ± 1.2 19.2 ± 0.4 22.0 ± 0.4 23.6 ± 0.3 20.3 ± 0.6
ATP 20.9 ± 1.2 20.5 ± 1.3 18.4 ± 1.4 19.0 ± 0.4 21.5 ± 0.4 22.6 ± 0.2 19.7 ± 0.6 0.86
Free Testosterone, ng/dL
Placebo 103 ± 13 112 ± 10 119 ± 6 111 ± 9 98 ± 6 100 ± 9 113 ± 12
ATP 112 ± 13 114 ± 9 118 ± 6 117 ± 11 108 ± 7 110 ± 10 125 ± 13 0.93
Total Testosterone, ng/dL
Placebo 591 ± 73 620 ± 58 625 ± 55 585 ± 58 551 ± 46 536 ± 88 605 ± 72
ATP 660 ± 67 645 ± 54 695 ± 60 645 ± 60 621 ± 49 592 ± 84 673 ± 69 0.83
PRSd
Placebo 9.1 ± 0.3 4.7 ± 0.4 7.0 ± 0.3 7.6 ± 0.2 4.8 ± 0.3 4.4 ± 0.3 7.6 ± 0.2
ATP 9.6 ± 0.2 4.9 ± 0.4 7.5 ± 0.3 8.2 ± 0.3 5.5 ± 0.4 5.5 ± 0.4 8.6 ± 0.4 0.61
aMean ± SEM for n = 11 ATP (400 mg ATP/d taken 30 min prior to exercise) and n = 10 placebo supplemented participants.
bProbability of treatment by time difference between the placebo and the ATP treatments over the 12-week study. The mixed model in SAS® was used with the
main effects of treatment, week and treatment by week, with the value for week 0 used as a covariate. The mixed model in SAS® was also used for 3MH:Cr:
however, 3MH:Cr was measured only at weeks 0, 1, 8, 9, and 10. The model used these values with week 0 as a covariate for determining the overall treatment by
time effect for 3MH:Cr.
cNot measured.
dPerceived recovery score is rated on the participants feeling of recovery from the last workout on a scale of 0-10. 0-2 indicates poor recovery and an anticipated
decline in performance; 4-6 indicates low to moderate recovery and expected similar performance; and 8-10 indicates highly perceived recovery and expected
increases in performance.
#Significantly different than corresponding placebo, t-test (p < 0.05).
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http://www.nutritionandmetabolism.com/content/10/1/57supplemental ATP on physiological responses that would
improve long-term muscular performance. For example,
Jordan et al. [13] demonstrated that 14 days of orally
ingested ATP positively influenced exercise performance.
Specifically, they demonstrated that 225 mg per day of
ATP for 14 days resulted in within-group increases in set-
one total repetitions performed and bench press total
training volume. More recently, Rathmacher et al. [14]
found that 400 mg of supplemental ATP per day for 15
days was effective in improving set-two leg muscle mini-
mum peak torque and tended to decrease set-three leg
muscle fatigue during three successive sets of knee exten-
sion exercises. Interestingly, the changes observed during
the aforementioned studies occurred despite final ATP
supplementation being provided to test participants 3 [13]
and 12 hours [14] prior to post-testing data collection.The prolonged lag time between supplementation and
testing may explain the inconclusive, albeit within-
group significant effects observed by Jordan et al. [13]
and the somewhat minimal but between group effects
on torque and fatigue observed by Rathmacher et al.
[14] Furthermore, since the 400 mg per day dose used
by Rathmacher et al. [14] was divided into two doses
throughout the day, the effective pre-exercise testing
dose consumed prior to the 12-hour supplement with-
drawal would have only been 200 mg of ATP.
The current investigation employed once per day sup-
plementation of a 400 mg dose of ATP where on training
and testing days participants consumed the supplement
30 minutes prior to exercise. We found the ATP supple-
mentation resulted in strength increases for the squat and
deadlift of 12.9% and 16.4%, respectively, when compared
Table 4 Blood chemistry values
Placebo ATP
Before* SEM† After SEM % Change Before SEM After SEM % Change p- Value‡
Glucose, mmol/l 4.48 0.08 4.51 0.09 0.6 4.62 0.07 4.65 0.04 0.7 1.00
Uric acid, mmol/l 0.29 0.02 0.29 0.02 1.0 0.29 0.02 0.29 0.01 1.3 0.99
Blood Urea Nitrogen, mmol/l 5.61 0.26 5.75 0.30 2.6 5.63 0.18 5.67 0.21 0.6 0.99
Creatinine, μmol/l 87.0 2.4 89.1 4.2 2.5 86.2 2.3 85.0 4.0 −1.5 0.80
eGRF, ml/min 101 2.2 101 3.6 0.6 105 3.7 107 3.7 1.7 0.93
Sodium, mmol/l 140 0.6 140 0.4 0.1 139 0.5 140 0.5 0.5 0.64
Potassium, mmol/l 4.3 0.1 4.3 0.1 −0.2 4.4 0.1 4.4 0.1 0.0 0.68
Chloride, mmol/l 101 0.4 101 0.4 −0.1 100 0.5 101 0.5 0.5 0.31
CO2, mmol/l 24.8 0.6 25.1 0.4 1.2 24.6 0.3 24.2 0.4 −1.5 0.77
Calcium, mmol/l 2.40 0.03 2.39 0.03 −0.2 2.44 0.02 2.43 0.02 −0.5 0.98
Protein, g/l 72.0 1.1 72.2 1.5 0.3 72.5 1.0 72.7 1.0 0.2 0.98
Albumin, g/l 46.6 0.5 46.0 0.8 −1.3 46.7 0.7 46.3 0.7 −0.8 0.53
Globulin, g/l 26.0 0.6 26.1 0.7 0.4 24.6 0.6 24.6 0.4 0.0 0.97
A:G Ratio 1.80 0.05 1.77 0.06 −1.6 1.91 0.06 1.89 0.05 −1.1 0.57
Total Bilirubin, μmol/l 13.4 2.5 12.9 2.6 −3.8 9.8 1.3 9.6 1.3 −1.7 0.71
Alkaline Phosphatase, IU/l 77.1 3.2 82.1 3.6 6.5 80.2 4.4 79.7 4.5 −0.6 0.16
Aspartate Aminotransferase, IU/l 25.0 1.9 24.0 2.0 −4.0 24.8 1.5 24.9 1.4 0.4 0.49
Alanine Aminotransferase, IU/l 26.6 2.8 26.6 2.8 0.0 22.1 2.0 22.3 1.9 0.8 0.90
*Values before and after 12 weeks of either placebo or ATP (400 mg/d) administration.
†Standard error of the mean.
‡p- value for Trt*time effect, the model included data from weeks 4 and 8 (not shown).
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http://www.nutritionandmetabolism.com/content/10/1/57to RT alone in the placebo (4.4% and 8.5%). In comparison
to the two former studies, it is likely that the more robust
changes observed within the current investigation are the
result of total ATP dose and dose timing relative to testing
procedures.
With regard to muscle power, we found that vertical
jump peak power was more responsive to ATP supple-
mentation (+15.3%) as compared to placebo (+11.5%).
Rathmacher et al. [14] have speculated that supplemen-
tal ATP may provide cumulative benefits in strenuous,
repetitive, and exhaustive exercise activities, which could
lead to improvements in muscle responses. However, we
have to point out that the mechanisms that ATP medi-
ates changes in skeletal muscle performance are still
under investigation and need to be fully elucidated. It
can be speculated that these functional changes are a
factor of small, transient increases in extracellular ATP
and its metabolites. For example, Sandona et al. [25]
presented evidence that [ATP]ex increases skeletal
muscle Ca2+ influx and the release of Ca2+ from the
sarcoplasmic reticulum, thereby affecting muscle con-
tractile properties. Specifically, increasing skeletal muscle
Ca2+ influx and intracellular concentrations have been
shown to significantly increase both the total number of
thin filaments binding and the speed at which the fila-
ments slide [26]. These aforementioned findings providea clue as to how the ATP supplementation might modu-
late the increases in muscle strength and power. How-
ever, these speculations must be eventually validated
with direct research.
The effects of ATP on skeletal muscle mass and changes
in lean body mass
To our knowledge, this study represents the first formal
investigation of the effects of oral ATP supplementation
on lean body mass and muscle thickness following a
chronic RT program. Our results indicated greater
increases in LBM and muscle thickness in response to
oral ATP versus placebo. We can speculate on a number
of possible reasons for the ergogenic effects of ATP on
muscle mass we have observed. In addition to ATP’s
capacity to buffer fatigue during repeated high volume
sets and increase total training volume, the supplement
may increase skeletal muscle blood flow, thereby enhan-
cing muscle O2 recovery. This is critical as muscle de-
oxygenation is associated with decreased performance
under repeated high intensity contractions [27]. Speci-
fically, extracellular ATP directly promotes the increased
synthesis and release of nitric oxide (NO) and prostacyc-
lin (PGl2) within skeletal muscle and therefore directly
affects tissue vasodilation and blood flow [28]. This is
supported by research suggesting increased vasodilation
Table 5 Blood hematology values
Placebo ATP
Before* SEM† After SEM % Change Before SEM After SEM % Change p Value‡
WBC, x109/l 5.93 0.38 5.98 0.34 0.8 6.08 0.24 6.07 0.22 −0.1 0.67
RBC, x1012/l 5.16 0.10 5.19 0.09 0.7 5.13 0.04 5.07 0.05 −1.1 0.30
Hemoglobin, g/l 156 2.8 155 2.4 −1.0 157 2.2 156 2.0 −0.8 0.97
Hematocrit, l/l 0.46 0.01 0.46 0.01 0.0 0.47 0.01 0.46 0.01 −1.8 0.54
MCV, μm3 89.7 0.8 89.3 1.0 −0.5 90.6 0.8 89.7 0.8 −1.0 0.94
MCH, pg/cell 30.5 0.40 30.2 0.33 −1.1 30.4 0.32 30.5 0.44 0.3 0.42
MCHC, g/l 339 3.1 336 2.5 −0.9 334 3.9 340 4.4 2.1 0.16
RDW,% 13.4 0.1 13.4 0.1 0.0 13.1 0.1 13.2 0.1 0.8 0.62
Platelets, x109/l 247 9.0 236 9.1 −4.2 248 9.5 217 5.1 −12.5 0.64
Neutrophils,% 46.5 3.1 47.4 2.5 1.9 47.6 3.0 47.8 2.0 0.5 0.80
Lymphocytes,% 39.6 3.2 38.4 2.6 −3.0 39.0 2.8 38.8 1.7 −0.6 0.74
Monocytes,% 10.3 0.6 9.4 0.7 −8.7 9.3 0.5 9.6 0.6 3.0 0.57
Eosinophils,% 3.6 0.5 3.6 0.5 0.0 3.4 0.4 3.4 0.4 0.0 0.98
Basophils,% 0.6 0.2 0.7 0.2 16.7 0.4 0.2 0.4 0.2 −0.3 0.83
Neutrophils, x109/l 3.2 0.6 3.3 0.5 2.5 3.0 0.3 2.9 0.2 −2.3 0.27
Lymphocytes, x109/l 2.4 0.2 2.5 0.3 4.1 2.4 0.2 2.4 0.1 2.9 0.99
Monocytes, x109/l 0.67 0.08 0.62 0.08 −7.5 0.82 0.20 0.61 0.05 −25.6 0.62
Eosinophils, x109/l 0.21 0.02 0.21 0.02 0.0 0.21 0.03 0.22 0.03 4.4 0.32
Basophils, x109/l 0.02 0.01 0.01 0.01 −50.0 0.00 0.00 0.00 0.00 0.0 0.41
*Values Before and After 12 weeks of either placebo or ATP (400 mg/d) administration.
†Standard error of the mean.
‡P value for Trt*time effect, the model included data from weeks 4 and 8 (not shown).
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http://www.nutritionandmetabolism.com/content/10/1/57and blood flow in response to intra-arterial infusion [29]
and exogenous administration of ATP. It can be specu-
lated that these changes in blood flow may lead to an in-
creased substrate pool for skeletal muscle by virtue of
increased glucose and O2 uptake [9]. If this is the case
the resulting outcome would be an improved recovery
response via a greater energetic environment for ana-
bolic processes capable of supporting exercise-induced
changes in LBM and hypertrophy. However, these are
currently only suggested possible mechanisms and need
to be verified in future research.
The effects of ATP on recovery from high intensity
training
Overtraining and overreaching are two of the most com-
plicated occurrences in sport. The primary tools utilized
to detect overtraining and overreaching include changes
in serum indices of skeletal muscle damage [30], anabolic
and catabolic hormone status [31], perceived recovery
[20], and muscle protein breakdown. However, the con-
sensus seems to dictate that the number one indicator of
overreaching and overtraining are short- and long-term
decrements in performance, respectively [32]. The cause
of overreaching appears to be an imbalance between train-
ing stimulus and recovery. If the stimulus exceeds theathlete’s adaptive capacity, decrements in performance will
result; ultimately taking weeks (overreaching) to months
(overtraining) to fully recover. For ethical reasons, a great
deal of research in strength and conditioning has centered
on overreaching protocols versus overtraining [32].
The present study attempted to overreach participants
through increasing training frequency and volume. Our
results indicated that the overreaching cycle was able to
decrease muscle power and strength, and overreaching
increased protein breakdown. However, these effects
were blunted in the ATP group. It is interesting to note
that protein breakdown was not blunted during phase 1
(weeks 1–8) by ATP supplementation. In fact, although
protein breakdown in the ATP supplemented group was
not significantly different than baseline, it appeared
slightly higher at week 8 relative to the control. We can
speculate that under normal conditions of training,
when glycogen levels are likely adequate those partici-
pants supplementing with ATP were able to maintain
higher intensities, which would result in higher rates of
protein breakdown. However, when exposed to greater
training frequencies, glycogen levels are likely to be de-
pleted, thus preventing higher intensities from being
performed. As such ATP supplementation is able to
blunt a rise in protein breakdown relative to a placebo
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crease fatigue resistance during a two-week intensive,
high-volume overreaching protocol. Following a two-week
taper in which volume was reduced, the placebo group
regained their baseline performance while the ATP group
experienced increases in both muscle strength and power.
These results indicate that a typical overreaching stimulus
overwhelms recovery capabilities in a non-supplemented
state. However, the ability for ATP to speed recovery may
provide athletes with a novel method to promote positive
training adaptations.
While at first look these results may appear to be only
pertinent to athletic performance, it is important to
understand that several non-sport activities place people
at risk for deterioration of performance in life threaten-
ing situations where performance is critical. A primary
example includes combat athletes / military personal
who are often times placed in extreme overreaching and
overtraining environments that may take months to re-
cover from [33]. These are often times highly condi-
tioned individuals whose lives and mission may depend
on the prevention of decay in strength, and power.
Effects of chronic ATP supplementation on safety
parameters
The results of this study suggest that 400 mg of oral
ATP administered daily had no effect on hemoglobin,
white blood cells, blood glucose, liver, or kidney func-
tion. These results are in agreement with Coolen et al.
[34] who reported that up to 5000 mg per day, during
28 days, of oral ATP resulted in no significant changes
in any blood or urine measured safety parameters.
Therefore, it appears likely that doses of 400 mg/day of
oral ATP for up to 12 weeks can be considered safe and
presented no clinically relevant adverse effects.
Bioavailability of oral ATP supplementation
Recently, Coolen et al. questioned the bioavailability of
oral ATP [2]. However, the biological pool where ATP is
measured will determine the results of bioavailability ana-
lysis. If sampled in venous portal blood, oral ATP is indeed
bioavailable [13]. Coolen et al. did not analyse venous por-
tal blood. If sampling systemic plasma or whole blood,
oral ATP will have very low bioavailability even in very
high doses. Paradoxically, Kichenin & Seman observed
that repeated administration of oral ATP led to progres-
sive diminution of plasma ATP [12]. Nevertheless, their
study demonstrated that oral ATP supplementation can
indeed produce biological responses. Over all, due to the
nature of the ATP molecule, its bioavailability is quite dif-
ficult to determine. While our results suggest that oral
ATP supplementation can significantly impact athletic
performance, skeletal muscle hypertrophy and recovery,
the current study did not utilize methodologies toinvestigate the potential mechanism(s) for the ergogenic
effects we observed.
Limitations
This study, similar to others, has limitations. This study
included all male subjects; therefore, future research will
need to expand our study design to a female population.
We also acknowledge that that these results occurred
with a highly trained population under extreme training
conditions. Chronic studies will need to be conducted in
untrained individuals under normal training loads.
Finally, we did not assess changes in muscular O2 con-
centrations or changes in intramuscular ATP. We sug-
gest that future researchers conduct these studies using
near infrared spectroscopy to access intramuscular O2
concentrations and magnetic resonance spectroscopy to
assess any changes in ATP charge. Without these mea-
sures, caution should be taken when interpreting the
actual mechanisms of action of the supplement.
Conclusions
The collective findings of our current study suggest that
oral supplementation with ATP in combination with high
intensity, periodized RT, increases muscle mass, strength,
and power compared with a placebo-matched control.
Moreover, when faced with greater training frequencies,
oral ATP may prevent typical declines in performance that
are characteristic of overreaching. Future research should
seek to elucidate the underlying mechanisms through
which ATP operates to promote improvements in training
adaptations.
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